

CHINA PHARMA HOLDINGS, INC.  
Form 8-K  
December 28, 2016

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 22, 2016

CHINA PHARMA HOLDINGS, INC.  
-----

(Exact name of Registrant as specified in charter)

<u>Nevada</u>	<u>001-34471</u>	<u>73-1564807</u>
(State or other jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification No.)

Second Floor, No. 17, Jinpan Road  
Haikou, Hainan Province, China 570216  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: +86 898-6681-1730 (China)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))

Item 8.01. Other Events.

China Pharma Holdings, Inc. (the "Company") received a notice from the Securities and Exchange Commission ("SEC") on December 22, 2016 informing the Company that the Public Company Accounting Oversight Board ("PCAOB") had revoked the registration of the Company's prior auditor, Arshak Davtyan, Inc.. The Company was informed that the prior auditor was no longer registered with the PCAOB, and that the Company may not include any audit reports or consents in its filings with the SEC from the prior auditor on or after the date of deregistration.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 28, 2016

CHINA PHARMA HOLDINGS, INC.

By: /s/ Zhilin Li  
Name: Zhilin Li  
Title: President and Chief Executive Officer

---